• 1
    Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989; 49: 64496465.
  • 2
    Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol. 1993; 66: 181196.
  • 3
    Ausprunk D, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res. 1977; 14: 5365.
  • 4
    Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res. 1986; 46: 467473.
  • 5
    Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 1999; 59: 47704775.
  • 6
    Horsman MR, Overgaard J. The oxygen effect and the tumour microenvironment. In: SteelGG, editor. Basic clinical radiobiology for radiation oncologists (3rd edition). London: Edward Arnold, 2002: 158168.
  • 7
    Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995; 333: 17571763.
  • 8
    Siemann DW, Warrington KH, Horsman MR. Targeting tumor blood vessels: an adjuvant strategy for radiation therapy. Radiother Oncol. 2000; 57: 512.
  • 9
    Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 1990; 9: 267282.
  • 10
    Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Br J Cancer. 1999; 80: 5764.
  • 11
    Siemann DW. Vascular targeting agents. Horizons Cancer Ther. 2002; 3: 415.
  • 12
    Woglom WH. A critique of tumour resistance. J Cancer Res. 1923; 7: 283311.
  • 13
    Coley Nauts H, Fowler GA, Bogatko FH. A review of the influence of bacterial infection and bacterial products (Coley's toxins) on malignant tumours in man. Acta Med Scand. 1953; 274: 2997.
  • 14
    Mottram JC. Observations on the combined action of colloidal lead and radiation on tumours. Br Med J. 1928; 1: 928.
  • 15
    Denekamp J, Hobson B. Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncol. 1983; 19: 271275.
  • 16
    Chaplin DJ, Horsman MR. The influence of tumour temperature on ischemia-induced cell death: potential implications for the evaluation of vascular mediated therapies. Radiother Oncol. 1994; 30: 5965.
  • 17
    Denekamp J. Endothelial cell attack as a novel approach to cancer therapy. Cancer Top. 1986; 6: 68.
  • 18
    Hirst DG, Denekamp J, Hobson B. Proliferation kinetics of endothelial and tumour cells in three mouse mammary carcinomas. Cell Tissue Kinet. 1982; 15: 251261.
  • 19
    Hobson B, Denekamp J. Endothelial proliferation in tumors and normal tissue: continuous labeling studies. Br J Cancer. 1984; 49: 405413.
  • 20
    Bicknell R, Harris AL. Anticancer strategies involving the vasculature: vascular targeting and the inhibition of angiogenesis. Semin Cancer Biol. 1992; 3: 399407.
  • 21
    Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, gustine HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000; 60: 13881393.
  • 22
    Burrows FJ, Derbyshire EJ, Tazzari PL, et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res. 1995; 1: 16231634.
  • 23
    Seon BK. Expression of endoglin (CD105) in tumor blood vessels. Int J Cancer. 2002; 99: 310311.
  • 24
    Brekken RA, Thorpe PE. Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res. 2003; 21: 42214229.
  • 25
    Veenendaal LM, Jin H, Ran S, et al. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A. 2002; 99: 78667871.
  • 26
    Brooks PC, Clark R, Cherish DA. Requirement of vascular integrin ανβ3 for angiogenesis. Science. 1994; 264: 569571.
  • 27
    Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998; 279: 377380.
  • 28
    Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res. 2001; 61: 711716.
  • 29
    Chang SS, O'Keefe DS, Bacich D, Reuter VE, Heston WD, Gaudin PD. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999; 5: 26742681.
  • 30
    Hill SA, Sampson LE, Chaplin DJ. Anti-vascular approaches to solid tumor therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer. 1995; 63: 119123.
  • 31
    Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. 1999; 19: 189195.
  • 32
    Baguley BC, Holdaway KH, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine. Evidence for a vascular mechanism. Eur J Cancer. 1991; 27: 482487.
  • 33
    Ludford RJ. Colchine in the experimental chemotherapy of cancer. J Natl Cancer Inst. 1945; 6: 89101.
  • 34
    Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997; 57: 18291834.
  • 35
    Li L, Rojiani A, Siemann DW. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys. 1998; 42: 899903.
  • 36
    Horsman MR, Ehrnrooth E, Ladekarl M, Overgaard J. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumours. Int J Radiat Oncol Biol Phys. 1998; 42: 895898.
  • 37
    Hori K, Saito S, Nihei Y, Suzuki M, Sato Y. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res. 1999; 90: 10261038.
  • 38
    Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys. 2002; 53: 164171.
  • 39
    Blakey DC, Westwood FR, Walker M, et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res. 2002; 8: 19741983.
  • 40
    Tozer GM, Prise VE, Wilson J, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 1999; 59: 16261634.
  • 41
    Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol. 2001; 77: 195204.
  • 42
    Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys. 2003; 57: 10471055.
  • 43
    Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer. 1999; 81: 13181327.
  • 44
    Galbraith SM, Chaplin DJ, Lee F, et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 2001; 21: 93102.
  • 45
    Baguley BC, Ching LM. DMXAA: an antivascular agent with multiple host responses. Int J Radiat Oncol Biol Phys. 2002; 54: 15031511.
  • 46
    Mahadevan V, Malik ST, Meager A, Fiers W, Lewis GP, Hart IR. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res. 1990; 50: 55375542.
  • 47
    Philpott M, Baguley BC, Ching LM. Induction of tumour necrosis factor α by single and repeated doses of the antitumor agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol. 1995; 36: 143148.
  • 48
    Zwi LJ, Baguley BC, Gavin JB, Wison WR. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst. 1989; 81: 10051013.
  • 49
    Bibby MC, Double JA, Loadman PM, Duke CV. Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. J Natl Cancer Inst. 1989; 81: 216220.
  • 50
    Ching LM, Joseph WR, Crosier KE, Baguley BC. Induction of tumor necrosis factor α messenger RNA in human and murine cells by the flavone acetic analogue 5,6-dimethylxanthenone-4-acetic acid (NSC64088). Cancer Res. 1994; 54: 870872.
  • 51
    Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer. 1998; 78: 439445.
  • 52
    Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res. 2001; 156: 503509.
  • 53
    Laws AL, Matthew AM, Double JA, Bibby MC. Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer. 1995; 71: 12041209.
  • 54
    Siemann DW, Mercer E, Lepler SE, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer. 2002; 99: 16.
  • 55
    Rojiani AM, Li L, Rise L, Siemann DW. Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma. Acta Oncol. 2002; 41: 98105.
  • 56
    Landuyt W, Ahmed B, Nuyts S, et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys. 2001; 49: 443450.
  • 57
    Siemann DW, Shi W. Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Semin Radiat Oncol. 2003; 13: 5361.
  • 58
    Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys. 1994; 29: 373377.
  • 59
    Pruijn FB, van Daalen M, Holford NH, Wilson WR. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol. 1997; 39: 541546.
  • 60
    Grosios K, Loadman PM, Swaine DJ, Pettit GR, Bibby MC. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res. 2000; 20: 229233.
  • 61
    Nelkin BD, Ball DW. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep. 2001; 8: 157160.
  • 62
    Li L, Rojiani AM, Siemann DW. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncol. 2002; 41: 9197.
  • 63
    Pedley RB, Hill SA, Boxer GM, et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate. Cancer Res. 2001; 61: 47164722.
  • 64
    Wilson WR, Li AE, Cowan DS, Siim BG. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys. 1998; 42: 905908.
  • 65
    Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A4 disodium phosphate and radiation in murine tumours. Radiother Oncol. 2001; 60: 155161.
  • 66
    Horsman MR, Christensen KL, Overgaard J. Hydralazine-induced enhancement of hyperthermic damage in C3H mammary carcinoma in vivo. Int J Hyperthermia. 1989; 5: 123136.
  • 67
    Horsman MR, Murata R. Combination of vascular targeting agents with thermal or radiation therapy. Int J Radiat Oncol Biol Phys. 2002; 54: 15181523.
  • 68
    Murata R, Overgaard J, Horsman MR. Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys. 2001; 51: 10181024.
  • 69
    Eikesdal HP, Bjerkvig R, Mella O, Dahl O. Combretastatin A-4 and hyperthermia; a patent combination for the treatment of solid tumors. Radiother Oncol. 2001; 60: 147154.
  • 70
    Griffin RJ, Lee SH, Rood KL, et al. Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors. Neoplasia. 2000; 2: 555560.
  • 71
    Siemann DW, Rojiani AM. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys. 2002; 54: 15121517.
  • 72
    Horsman MR, Murata R, Overgaard J. Combination studies with combretastatin and radiation: effects in early and late responding normal tissues [abstract]. Radiother Oncol. 2002; 64: S50.
  • 73
    Dowlati A, Robertson K, Cooney M, et al. A Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002; 62: 34083416.
  • 74
    Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol. 2003; 21: 28152822.
  • 75
    Radema SA, Beerepoot LV, Witteveen PO, Gebbink MF, Wheeler C, Voest EE. Clinical evaluation of the novel vascular-targeting agent ZD6126: assessment of toxicity and surrogate markers of vascular damage [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 110a.
  • 76
    Gadgeel SM, LoRusso P, Wozniak AJ, Wheeler C. A dose-escalation study of the novel vascular-targeting agent ZD6126 in patients with solid tumors [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 110a.
  • 77
    Tolcher AW, Forero L, Celio P, et al. Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28 days [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 208.
  • 78
    Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol. 2003; 21: 28312842.
  • 79
    Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a Phase I trial of combretastatin A4 phosphate. J Clin Oncol. 2003; 21: 28232830.
  • 80
    DelProposto Z, LoRusso P, Latif Z, et al. MRI evaluation of the effects of the vascular-targeting agent ZD6126 on tumor vasculature [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 111a.
  • 81
    Galbraith SM, Rustin GJ, Lodge MA, et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol. 2002; 20: 38263840.
  • 82
    Rustin GJ, Bradley C, Galbraith S, et al. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: Phase I clinical and pharmacokinetic study. Br J Cancer. 2003; 88: 11601167.
  • 83
    Jameson MB, Thompson PI, Baguley BC, et al. Clinical aspects of a Phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer. 2003; 88: 18441850.